Chinese firms had enjoyed a privileged position because of the country’s regulatory system. Photo: Alamy
Pharma firms face shake-up with China’s plan to bulk-buy drugs
- Pilot programme involves major cities clubbing together to purchase certain medicines, driving down prices
- Chinese companies that have invested heavily in R&D stand best chance of survival
Chinese firms had enjoyed a privileged position because of the country’s regulatory system. Photo: Alamy
